Windtree Therapeutics (WINT) announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C and their use in treating ...

“Issuance of the new patent for our oncology preclinical aPKCi inhibitor pipeline is an important part of our development strategy,” said Jed Latkin, CEO of Windtree Therapeutics. “We will continue ...

(IGF1, insulin-like growth factor 1; MAPKAP-K1, mitogen-activated protein kinase (MAPK)-activated protein kinase 1; PDK1, 3-phosphoinositide-dependent protein kinase 1; PKB/AKT, protein kinase B ...

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...